National Institute for Bioprocessing Research and Training Facility Breaks Ground in Ireland
A ground breaking ceremony for the commencement of construction of the National Institute for Bioprocessing Research and Training (NIBRT) at Belfield Innovation Park in Dublin was held on November 29.
A ground breaking ceremony for the commencement of construction of the National Institute for Bioprocessing Research and Training (NIBRT) at Belfield Innovation Park in Dublin was held on November 29. The investment, in the region of €50 million, is funded by IDA Ireland.
NIBRT is an independent national institute owned by the collaborating academic institutions—University College Dublin, Trinity College Dublin, Dublin City University, and Institute of Technology Sligo—and run by an industry-focused board. Its training and research programs have been underway since NIBRT’s founding in 2006, using the facilities at the four colleges and in conjunction with other training and education establishments throughout Ireland.
The new NIBRT facility will include state-of-the-art dedicated training facilities, aimed at ensuring Ireland has a specialized workforce to capture this growing sector, and its scale-up expertise and leading edge equipment will help the industry to solve its technical challenges and improve its processes.
The biopharmaceutical sector was identified as a key focus area for Ireland’s future development by the Irish government’s Technology Foresight study in 1998. That report noted that as traditional pharmaceutical companies expand into biopharmaceuticals, new skills sets are required to make the transition This assessment prompted the government to invest in supporting the industry by helping the workforce pool develop industry relevant skills and by supporting bioprocess research aimed at improving quality and yield.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Biophysical and Aggregate Characterization for the Development of Biologics
June 10th 2025This eBook explores how advanced particle analysis technologies are revolutionizing biologic drug development. It highlights the importance of accurately identifying and characterizing subvisible particles to ensure drug safety, stability, and regulatory compliance. Techniques like Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM) are often used for their capabilities in detecting protein aggregates and degraded excipients such as polysorbates. Case studies and experimental results demonstrate how these tools provide high-throughput, low-volume analysis that enhances decision-making in formulation screening and manufacturing.
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
